<DOC>
	<DOCNO>NCT00041132</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Monoclonal antibody rituximab locate cancer cell either kill deliver cancer-killing substance without harm normal cell . Combining rituximab chemotherapy may kill cancer cell . PURPOSE : Phase II pilot study study effectiveness combine chemotherapy rituximab treat patient newly diagnose mantle cell lymphoma .</brief_summary>
	<brief_title>S0213 Chemotherapy Plus Rituximab Treating Patients With Mantle Cell Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine 1-year progression-free survival probability patient previously untreated mantle cell lymphoma treat course rituximab cyclophosphamide , doxorubicin , vincristine , dexamethasone alternating course rituximab high-dose cytarabine methotrexate leucovorin calcium . - Determine response rate ( complete unconfirmed complete partial response ) survival patient treat regimen . - Determine toxicity regimen patient . - Correlate chromosomal breakpoints , translocate immunoglobulin regulatory sequence , cyclins D1 , D2 , D3 response progression-free survival patient treat regimen . - Correlate gene expression ( measure DNA microarray analysis ) response progression-free survival patient treat regimen . OUTLINE : This pilot , multicenter study . - Courses 1 , 3 , 5 , 7 : Patients receive rituximab IV day 1 ( course 1 , 3 , 5 ) ; cyclophosphamide IV 3 hour twice day day 2-4 ; doxorubicin IV 24 hour day 5-7 ; vincristine IV day 5 12 ; dexamethasone orally IV four time day day 2-5 12-15 ; filgrastim ( G-CSF ) subcutaneously ( SC ) daily begin day 8 continue blood count recover . - Courses 2 , 4 , 6 , 8 : Patients receive rituximab IV day 1 ( course 2 , 4 , 6 ) ; high-dose methotrexate IV 24 hour day 2 ; high-dose cytarabine IV 2 hour twice day day 3-4 ; oral leucovorin calcium 4 time day day 3-10 ; G-CSF SC daily begin day 5 continue blood count recover . Courses repeat every 21 day absence disease progression unacceptable toxicity . Patients follow within 30 day , every 3 month 2 year , every 6 month 3 year . Patients disease progression follow annually 5 year study entry . PROJECTED ACCRUAL : Approximately 50 patient accrue study within 25 month .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven stage III/IV bulky stage II mantle cell lymphoma one follow histologic subtypes : Nodular Diffuse Mantle zone Blastic Newly diagnose previously untreated disease Bidimensionally measurable disease PATIENT CHARACTERISTICS : Age : 18 69 Performance status : Zubrod 02 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,000/mm^3 Platelet count least 100,000/mm^3 ( 50,000/mm^3 marrow involvement present ) Hepatic : Bilirubin great 1.5 mg/dL ( 5.0 mg/dL hepatic involvement present ) Renal : Creatinine great 2.0 mg/dL Creatinine clearance great 50 mL/min Cardiovascular : Ejection fraction least 50 % MUGA 2D echocardiogram No significant abnormality EKG Other : Not pregnant nursing Fertile patient must use effective contraception Willing receive blood product transfusions No known sensitivity E. coliderived proteins No known AIDS syndrome HIVassociated complex No malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer carcinoma situ cervix PRIOR CONCURRENT THERAPY : Biologic therapy : No prior monoclonal antibody therapy Chemotherapy : No prior chemotherapy lymphoma Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy lymphoma Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>contiguous stage II mantle cell lymphoma</keyword>
	<keyword>noncontiguous stage II mantle cell lymphoma</keyword>
</DOC>